We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Agreement Will Hasten Development of Alzheimer's Disease Diagnostic Test

By LabMedica International staff writers
Posted on 16 Dec 2009
The availability of an Alzheimer's disease (AD) test targeted to the protein p97 will enable earlier diagnosis, quantitative disease monitoring, and better patient outcomes. More...
The p97 protein is a secreted protein specifically expressed by amyloid plaque-associated reactive microglia.

biOasis Technologies Inc. (South Surrey, BC, Canada) announced that a major step in the application of its p97 test for diagnosis of Alzheimer's disease was achieved by the signing of an agreement with UK-based Fleet Bioprocessing Ltd. (Fleet; Hartley Whitney, UK).

Rob Hutchison, CEO, biOasis commented, ''If earlier diagnosis and improved patient management result in delaying the average onset of the disease by even one-year, society would save in excess of U.S. $12 billion annually. The agreement with Fleet will reduce product development timelines for the biOasis p97 Alzheimer's test and enable faster entry into the $36 billion IVD market."

Fleet Bioprocessing are expert providers of high-quality contract development and manufacturing services. They meet the needs of the diagnostics, pharma, and biotech sectors, offering a range of services from purification and conjugation of proteins, through to immunoassay development and the formulation and dispensing of reagents.

biOasis Technologies Inc. is a company focused on the Health Care & Life Sciences market, and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases.

Related Links:
biOasis Technologies Inc.
Fleet Bioprocessing Ltd.



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.